Revenue/EBITDA forecasts" ... forecasting fiscal 2020 (year end December 31) revenue and EBITDA of $40.3 million and $4.9 million, respectively, fiscal 2021 revenue and EBITDA of $293.4 million and $70.0 million, respectively, and fiscal 2022 revenue and EBITDA of $381.4 million and $125.4 million, respectively. (All figures in US dollars except where noted otherwise.)"
https://www.cantechletter.com/2020/10/red-white-bloom-has-a-381-per-cent-upside-says-pi-financial/
If they can show positive EBITDA right out of the gate (as opposed to massive losses racked up by many CAD pot companies), this will be hugely positive. They seem to be using Trulieve as their business model, focusing on select States.
https://www.thecannabisinvestor.ca/this-u-s-cannabis-stock-appears-to-be-way-undervalued-and-may-actually-benefit-from-a-second-wave-of-the-pandemic/
Red White & Bloom is projecting 2020 revenue of $166 million and EBITDA of $57.5 million according to the company’s most recent
investor presentation. Those are serious numbers that should soon catapult the company into the upper echelon of the burgeoning U.S. cannabis industry. Still, there is currently a disconnect between future earnings and RWB’s current share price. The situation has created an opportunity for investors that doesn’t present itself that often. If management forecasts are correct, then the price of RWB’s stock stands to rise substantially from current levels.